ngue-Endemic Regions (DEN-301). Oral presentation at: World Congress of the World Society for Pediatric Infectious Diseases (WSPID 2025), October 29, 2025. Bangkok, TH. OP010.
3ClinicalTrials.Gov.Efficacy, Safety and Immunogenicity of Takeda’s Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES). Retrieved November 2025.
4World Health Organization (WHO) Technical Report Series No. 979, 2013 Annex 2. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated).https://cdn.who.int/media/docs/default-source/biologicals/vaccine-standardization/dengue/trs-979-annex-2-dengue.pdf?sfvrsn=bd659777_2&download=true.
5Murray, et al. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013 Aug 20;5:299-309. doi: 10.2147/CLEP.S34440.
6Huang CY-H, et al. Genetic and phenotypic characterization of manufacturing seeds for tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7:e2243
7Takeda.QD
=*=*=*=*=*=
当前为第20/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页